OncoGenex cancer news
OncoGenex will reduce headcount by 11 (27%) to 30 to focus on reaching several near-term clinical milestones for custirsen and apatorsen.
Gathering data...
Products & Solutions
About Biocentury
Contact
Privacy & Legal
- Follow Us
Gathering data...
OncoGenex will reduce headcount by 11 (27%) to 30 to focus on reaching several near-term clinical milestones for custirsen and apatorsen.